Detalhe da pesquisa
1.
How I treat non-transfusion-dependent ß-thalassemia.
Blood
; 142(11): 949-960, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37478396
2.
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Br J Haematol
; 204(4): 1232-1237, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311378
3.
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
Haematologica
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546692
4.
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): The Mayo Clinic experience.
Haematologica
; 2024 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38899336
5.
Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.
Haematologica
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813716
6.
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Haematologica
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572562
7.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Am J Hematol
; 99(2): 193-202, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071734
8.
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.
Cancer
; 129(6): 934-945, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545710
9.
Innovation in Resident Core Oncology Education: Switching from an Inpatient Ward Rotation to a Hybrid Model of Inpatient Consultations and Outpatient Clinics.
J Cancer Educ
; 37(6): 1768-1772, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33987745
10.
Outcomes of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy.
Pacing Clin Electrophysiol
; 44(4): 625-632, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33592678
11.
Thalassemia in the emergency department: special considerations for a rare disease.
Ann Hematol
; 99(9): 1967-1977, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32621178
12.
The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: Giant strides and ongoing challenges.
Am J Hematol
; 98(3): 374-376, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36540957
13.
Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing.
Am J Hematol
; 98(8): 1168-1170, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37314420
14.
Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
Int J Mol Sci
; 19(1)2018 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29316681
15.
Psycho-oncology in the Arab world: The time is now.
Psychooncology
; 31(1): 148-151, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34390087
16.
Safety and pharmacokinetics of the oral iron chelator SP-420 in ß-thalassemia.
Am J Hematol
; 92(12): 1356-1361, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28940308
17.
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
Am J Hematol
; 97(7): E232-E235, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35338673
18.
The Lebanese healthcare sector: The point of exsanguination.
Am J Hematol
; 96(11): E403-E404, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416043
19.
A land in agony: COVID-19, economic collapse, political corruption, and a deadly blast.
Am J Hematol
; 96(1): E1-E2, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33085779
20.
Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.
Am J Hematol
; 96(11): E433-E436, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34428328